BioSpace News Archive

Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG ® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML – OPTIC Trial Evaluating Response-Based Dosing Regimens of ICLUSIG for the Treatment of Resistant / Intolerant Chronic-Phase CML Demonstrates Durable, Clinically Meaningful Depth of Response While Managing Arterial Occlusive Event Risk

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated results of their first-in-human multicenter study of GC012F for the treatment of multiple myeloma

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021. Puma will present three posters with audio recordings, the corresponding abstracts of which are now live on the 2021 ASCO Annual Meeting website.

In this first reported Phase 1b cohort, the etrumadenant-based combination was well tolerated with a composite overall response rate (ORR) of 41% in people previously treated for metastatic castrate-resistant prostate cancer (mCRPC) Etrumadenant is the first dual adenosine A 2a /A 2b receptor antagonist to demonstrate evidence of clinical activity in prostate cancer

Updated results from phase I dose expansion in head and neck cancer showed durable signs of efficacy at a median follow up of 8.1 months, with an overall objective response rate of 82.5% and a complete response rate of 62.5% Data from the expansion part of the study continue to support NBTXR3 as feasible and well-tolerated in highly vulnerable patients with high unmet needs and significant burden of disease

Clinical benefit observed in 1-year overall survival with addition of sotigalimab to standard of care gemcitabine/nab-paclitaxel; 48.1% as compared to the 35% historical standard of care control

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will present results from a study with more than 275,000 women validating the use of a new method for polygenic breast cancer risk assessments in women of all ancestries. The new data will be shared in an oral presentation with leading collaborators on June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Bicara Therapeutics , a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumor microenvironment, today announced that a digital presentation with clinical data from its ongoing Phase 1/2 study of BCA101, a bifunctional antibody designed to target the TGFβ trap to EGFR+ tumors, will be presented at the American Society of Clinical Oncology

Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, today announced that the management team will participate at the Craig-Hallum Institutional Investor Conference on Wednesday, June 2, 2021.

Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerability with no dose-limiting toxicities; preliminary clinical activity of uliledlimab has been observed in patients with advanced cancers